Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05865028 · ClinicalTrials.gov registry record · Phase 2
A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia
A Phase 2 study of Oropharyngeal Dysplasia and Oral Cavity Dysplasia, sponsored by Elizabeth J Franzmann.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT05865028 is a Phase 2 study of Oropharyngeal Dysplasia and Oral Cavity Dysplasia that is actively recruiting participants, run by Elizabeth J Franzmann. The registered enrollment target is 32 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05865028, a Phase 2 study of Oropharyngeal Dysplasia and Oral Cavity Dysplasia, is actively recruiting participants, sponsored by Elizabeth J Franzmann.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess whether APG-157 can reduce the tumor size in participants with the study disease. Another purpose is to find out about the effects of APG-157 on certain tumor markers and oral rinses in participants with the study disease.
Conditions Studied
Interventions
- DRUG APG-157
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-05-24 |
| Est. Completion | 2028-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05865028
The ClinicalTrials.gov registry entry for NCT05865028 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elizabeth J Franzmann, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Oropharyngeal Dysplasia appearing as the primary indexed condition, and to 1 intervention - of which APG-157 is the first listed.
NCT05865028 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05865028 about?
NCT05865028 is a clinical study titled "A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia". The purpose of this study is to assess whether APG-157 can reduce the tumor size in participants with the study disease. Another purpose is to find out about the effects of APG-157 on certain tumor markers and oral rinses in participants with the study disease.
What is the current status of trial NCT05865028?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2023-05-24. Estimated completion is 2028-05-24.
What conditions does trial NCT05865028 study?
This clinical trial studies the following conditions: Oropharyngeal Dysplasia, Oral Cavity Dysplasia, Oral Carcinoma in Situ.
What interventions are being tested in trial NCT05865028?
The interventions under investigation include: APG-157 (DRUG).
Who is sponsoring clinical trial NCT05865028?
This trial is sponsored by Elizabeth J Franzmann, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05865028 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.